Two pharmaceutical companies are competing for the first copy of permadomide, which has an annual sales volume of more than $2 billion

[pharmaceutical network industry trends] with the rapid development of tumor medicine, the mechanism of tumor occurrence and development is becoming more and more clear, and the market of tumor targeted drugs is also expanding rapidly All tumor targeting drugs have met the expectations of the public, and they have emerged in the global drug market Major enterprises are also constantly focusing on innovative research, development and imitation of drugs in this area Recently, it has been reported that the second acceptance number of three types of generic listing applications for pomadomide capsule of Yangzijiang Pharmaceutical Co., Ltd has also entered the stage of "review and approval", and will compete with Zhengda Tianqing for the first generic product in China At present, the popular drugs in the global market include thalidomide, lenalidomide and pomadolamine With excellent performance, lenalidomide has become a magic drug in the field of blood cancer As a new generation of product, pomadolamine's subsequent explosive power is highly valued by the market But at present, the original research has not been listed in China, so the treatment of patients is inconvenient and the cost is high Pamidramine is a kind of immunomodulator, and also a very active immunomodulator, which can inhibit the proliferation of hematopoietic tumor cells and induce apoptosis Pamidramine is suitable for patients with multiple myeloma who have received at least two previous treatments, including lenalidomide and bortezomib, and have been confirmed to have progressed or completed the last treatment within 60 days It can also provide new treatment options for patients who have failed to receive other drugs In the global market, pomadolamine has begun to have a hot trend, the market prospects are widely optimistic At present, the generic drugs of thalidomide and lenalidomide have been listed in the domestic market, and the sales growth rate is increasing year by year Thalidomide has been used in Suzhou Changzheng Xinkai Pharmaceutical Co., Ltd and Changzhou Pharmaceutical Co., Ltd for its capsules and tablets, both of which are class B products of national medical insurance The indications approved in China are leprosy control In 2018, the terminal sales volume in China is close to 200 million yuan, of which Changzhou pharmaceutical market share is 94.48% In 2013, the new lenalidomide capsule was approved to enter China In July 2017, 36 kinds of negotiation drugs, such as lenalidomide, were included in the 2017 national medical insurance catalogue (class B) In November of the same year, the first domestic lenalidomide capsule was approved to be produced by Beijing Shuanglu pharmaceutical industry In 2019, with the approval of 6 kinds of imitations of Zhengda Tianqing pharmaceutical and 4 kinds of imitations of Qilu pharmaceutical, the sales volume of products is expected to reach a new high In terms of consistency evaluation, Qilu pharmaceutical is deemed to have passed the approval according to the new classification The supplementary application status of Zhengda Tianqing Pharmaceutical Co., Ltd is "certificate preparation completed - to be approved" The supplementary application of Beijing Shuanglu Pharmaceutical Co., Ltd is under review and approval However, there is no application for import of pamidramine in China, and the first generic drug is still in the stage of deliberation The product was declared to be 1mg and 4mg on August 16, 2018 The chemical registration classification is 3.1, which is used to treat multiple myeloma This time, the second acceptance number of the three kinds of parody listing application of pamadomide capsule of Yangzijiang pharmaceutical entered the stage of "review and approval", which also made it a hot topic in the market for Yangzijiang and Zhengda Tianqing to win the first domestic parody of pamadomide From the current situation, the two are on a balance for the time being Since 2015, the state issued the opinions on reforming the review and approval system of medical devices, which stipulates that "the first generic drugs can enter the market after priority review and approval", the first generic drugs have been paid more and more attention Although there is not a perfect matching system of first generic drugs in China, the advantages of first generic drugs in pricing, registration, evaluation and other aspects are becoming increasingly obvious, which has become the focus of research and development layout of many domestic pharmaceutical enterprises For large domestic pharmaceutical enterprises, the first generic drug is not a common new product, but an extension of strategy and a deep ploughing in the field The competition for the first imitation can make concerted efforts to build brand image and product mix and form overall advantages Who can pass the examination and approval of Zhengda Tianqing and Yangzi River in the future will affect the subsequent development of the enterprise to a certain extent.